Ontario Immunization Advisory Committee (OIAC) Conflict of Interest Summary
The following is a list of members of the OIAC for which PHO has determined have conflicts. These declarations are provided to ensure transparency and accountability in the advisory process. Each member has disclosed any potential or actual conflicts of interest to maintain the integrity of the committee's work and ensure that recommendations are made in the best interest of public health.
|
Committee Member |
Disclosures |
|---|---|
|
Dr. Jeffrey Pernica |
AstraZeneca and Merck – Grant support for research activity. Abbot, bioMérieux, Diasorin – In-kind materials for research activity. |
| Dr. Juthaporn Cowan | Takeda – Honoraria for lecture and consultation in 2024 |
|
Dr. Sherilyn Houle |
Bavarian Nordic, GSK, Merck, Moderna, Pfizer, Seqirus, Valneva – Advisor Board travel and honoraria, speaker fees and travel reimbursement and independent research grants |
|
Dr. Allison McGeer |
Astra-Zeneca, Cidara, GSK, Leyden Laboratories, Janssen, Merck, Moderna, Pfizer, Sanofi Pasteur and Seqirus - Compensation and honoraria of travel reimbursement. Sienna Living – Consulting (unpaid). |
|
Dr. Matthew Miller |
Seqirus, GSK, Roche, Sanofi, Grifols, Aramis Biotechnologies, StokedBio - Member of Scientific Advisory Boards with honoraria. Zentek, Providence Therapeutics, and JN Nova - conducted research. Co-Founder and Chief Scientific Officer of AeroImmune Inc. |
Mitigation strategy: Mitigation strategies are in place to manage each conflict individually on a case-by-case basis.
Note: This summary is intended to provide transparency regarding potential conflicts of interest for members of the OIAC. The full declarations are kept on record for internal review and reference.
MyPHO
Don’t have a MyPHO account? Register Now